C4X Discovery Selects Once-Daily Oral α4β7 Inhibitor Candidate for Inflammatory Bowel Disease Treatment
核心洞察
C4X Discovery has selected a potential best-in-class pre-clinical candidate from its oral α4β7 integrin inhibitor (搜索) programme for treating inflammatory bowel disease (搜索).
The selected candidate supports once-daily dosing and could provide a more convenient treatment option for IBD (搜索) patients compared to current biologics.
The company has developed a genetic biomarker for α4β7 (搜索) inhibition response that could enable personalized treatment approaches.
C4X Discovery Holdings Ltd (搜索) announced on September 22, 2025, the selection of a potential best-in-class pre-clinical candidate from its oral α4β7 integrin inhibitor (搜索) programme for treating inflammatory bowel disease (搜索) (IBD (搜索)). The selected compound is designed as a potent and selective α4β7 (搜索) inhibitor with oral bioavailability to support once-daily dosing, presenting what the company describes as a potentially transformative oral therapy for IBD patients.
Addressing Significant Market Need
IBD (搜索) affects more than five million people worldwide and represents a rapidly growing market projected to reach USD 47.7 billion by 2034. According to C4X Discovery, many patients remain underserved by current therapies, creating an opportunity for their oral α4β7 integrin inhibitor (搜索) to deliver a much-needed, more convenient treatment option.
The convenience of a targeted oral α4β7 (搜索) inhibitor offers clear opportunities for oral therapies to advance ahead of biologics and significantly expand the number of treated patients. The company's approach can be combined with other targeted therapies for patients with complex or refractory disease where existing approaches have failed to deliver sufficient control.
Potential for Personalized Medicine
C4X Discovery has achieved what it describes as a breakthrough in developing a genetic biomarker of response to α4β7 (搜索) inhibition. This biomarker could enable more personalized treatment, supporting optimized clinical development and providing a pathway to patient stratification. By combining the established safety and efficacy of α4β7 inhibition with the convenience and accessibility of oral dosing, this treatment paradigm could potentially improve patient outcomes while reducing healthcare system burden.
Leadership Commentary and Strategic Direction
Nick Ray, Chief Scientific Officer of C4X Discovery, commented: "Advancing our oral α4β7 (搜索) programme to candidate selection represents a significant scientific achievement and validates our discovery approach. With additional data from our PAD4 (搜索) and TNFα (搜索) programmes expected in the coming months, we're progressing a focused pipeline targeting key pathways in immuno-inflammatory disease. These programmes address distinct but complementary mechanisms, creating potential therapeutic options both as individual treatments and in combination approaches across different inflammatory conditions."
Emma Blaney, CEO of C4X Discovery, stated: "C4XD (搜索) has a strong track record of partnering pre-clinical programmes at various stages in the drug discovery process. We plan to continue partnering discussions for our α4β7 (搜索) programme during the remainder of 2025 and expect to generate pivotal data on our other programmes in the coming weeks."
Broader Pipeline Development
C4X Discovery's pipeline spans several high-value immuno-inflammatory indications. The company is currently advancing best-in-class oral α4β7 (搜索) and TNFα (搜索) inhibitors alongside a first-in-class PAD4 (搜索) programme, encompassing both innovative monotherapies and strategic combination approaches across multiple therapeutic areas.
The company positions itself as a pioneering drug discovery organization that combines scientific expertise with cutting-edge technologies to efficiently deliver next-generation oral medicines. Their enhanced molecular design capabilities are demonstrated by three high-value programmes they have successfully out-licensed to date, generating robust small molecule drug candidates for disease-modifying targets with industry-leading safety profiles.